Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.53 | N/A | -12.09% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.53 | N/A | -12.09% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach due to current market conditions. They emphasized the importance of their ongoing projects but did not offer specific future guidance.
Management did not provide specific guidance for future quarters.
The company is focused on ongoing projects and maintaining operational stability.
The earnings report indicates that PTC Therapeutics is facing challenges, as evidenced by the EPS miss. The stock reacted negatively, dropping 2.32%, likely due to the lack of revenue information and forward guidance. Investors may be concerned about the company's financial outlook without clearer direction from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BERKLEY W R CORP
Oct 24, 2022